European journal of immunology · 2026
Stable β2-Microglobulin-HLA Class I Association Reshapes the Antigenic Landscape and TCR Recognition of Cancer-Associated Epitopes.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Barajas Molina Ana, Horokhovskyi Yehor, Acuti Nicole, Chong Yee Kien, Phanichkrivalkosil Meghna, Siddons Sophie, Afrache Hassnae, Maloney Megan, Soh Wai Tuck, Hofland Tom, Hall Callum, Urlaub Henning, Kassiotis George, Liepe Juliane, Mishto Michele
Аннотация
β2-Microglobulin (β2m) is essential for the stability and surface expression of human leukocyte antigen class I (HLA-I) molecules. While β2m's structural role is well established, its influence on the antigenic landscape remains incompletely understood. Here, we investigated how constitutive β2m binding to HLA-I influences the antigenic landscape in the context of cancer-associated epitopes. Using two engineered cell lines expressing β2m fused to the HLA-I heavy chain, we analysed changes in immunopeptidomes and epitope presentation. Despite cell line-specific transcriptional responses, the fusion of β2m to HLA-I consistently reduced peptide editing and resulted in convergent remodelling of the antigen presentation pathway (APP). The fusion further altered peptide selection, favouring the display of lower-affinity peptides derived from endogenous proteins while impairing high-affinity peptide presentation on HLA-I molecules. These changes were not attributable to APP component abundance but rather reflected mechanistic alterations in peptide selection and impacted T cell receptor recognition of tumour epitopes. Our findings suggest that β2m-HLA-I fusion can distort the physiological antigenic repertoire and T cell recognition, with implications for epitope discovery, immunotherapy design, and studies of HLA-I-mediated immune surveillance.